Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti–neutrophil cytoplasmic antibody vasculitis
- 7 September 2021
- journal article
- letter
- Published by Elsevier BV in Kidney International
- Vol. 100 (5), 1124-1127
- https://doi.org/10.1016/j.kint.2021.08.020
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersThe New England Journal of Medicine, 2021
- Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case SeriesAnnals of Internal Medicine, 2021
- Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et alAnnals Of The Rheumatic Diseases, 2021
- Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 DosesJAMA, 2021
- Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for NephrologistsKidney International Reports, 2021
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trialArthritis & Rheumatism, 2009